[Bioavailability of two slow-release formulations of verapamil]. 1990

B Keller-Stanislawski, and N Rietbrock
Abtielung für Klinische Pharmakologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main.

The bioavailability of 2 slow release formulations (test (P) and reference (R)) of verapamil was investigated in a study with a randomised cross over design, 20 healthy male subjects were included. The mean peak plasma concentration (36.1 +/- 13.1 ng/ml) of the test preparation was reached after 3.75 +/- 0.8 h. The control preparation (R) produced peak values of 34.4 +/- 8.1 ng/ml after 5.6 +/- 3.1 h. MRT (P) was 17.6 +/- 8.2 h and for (R) was 21.1 +/- 7.5 h after (R). The 95-%-confidence interval of the two preparations differed by more than 20%. The release rate of (P) is slower than that of (R).

UI MeSH Term Description Entries
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

B Keller-Stanislawski, and N Rietbrock
April 1988, British journal of clinical practice. Supplement,
B Keller-Stanislawski, and N Rietbrock
August 1992, Archiv der Pharmazie,
B Keller-Stanislawski, and N Rietbrock
June 1985, British journal of clinical practice. Supplement,
B Keller-Stanislawski, and N Rietbrock
December 1987, International journal of clinical pharmacology, therapy, and toxicology,
B Keller-Stanislawski, and N Rietbrock
April 2002, International journal of clinical pharmacology and therapeutics,
B Keller-Stanislawski, and N Rietbrock
January 1992, Journal of pharmaceutical and biomedical analysis,
B Keller-Stanislawski, and N Rietbrock
September 1986, Journal of veterinary pharmacology and therapeutics,
B Keller-Stanislawski, and N Rietbrock
August 1990, Acta neurologica Scandinavica,
B Keller-Stanislawski, and N Rietbrock
March 1997, Anales de medicina interna (Madrid, Spain : 1984),
B Keller-Stanislawski, and N Rietbrock
March 1992, Epilepsy research,
Copied contents to your clipboard!